Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Buy
65
ZVSA Quote, Financials, Valuation and Earnings
Last price:
$0.27
Seasonality move
:
-20.68%
Day range:
$0.17 - $0.27
52-week range:
$0.11 - $1.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.19x
Volume:
1.5M
Avg. volume:
97K
1-year change:
-77.53%
Market cap:
$2.1M
Revenue:
--
EPS (TTM):
-$5.05
Analysts' Opinion
-
Consensus RatingZyVersa Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $70.00, ZyVersa Therapeutics, Inc. has an estimated upside of 7441.48% from its current price of $0.27.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $0.27.
Fair Value
-
According to the consensus of 1 analyst, ZyVersa Therapeutics, Inc. has 7441.48% upside to fair value with a price target of $70.00 per share.
ZVSA vs. S&P 500
-
Over the past 5 trading days, ZyVersa Therapeutics, Inc. has overperformed the S&P 500 by 94.12% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ZyVersa Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ZyVersa Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter ZyVersa Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
ZyVersa Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter ZyVersa Therapeutics, Inc. reported earnings per share of -$2.56.
Enterprise value:
1.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-157.27%
Net Income Margin (TTM):
--
Return On Equity:
-711.85%
Return On Invested Capital:
-711.85%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$10.4K | -$17.4K | -- | -$1.7K | -- | |
| Operating Income | -$17.8M | -$9.6M | -$7.6M | -$2.3M | -$2.1M | |
| EBITDA | -$17.8M | -$9.6M | -$7.6M | -$2.3M | -$2.1M | |
| Diluted EPS | -$2,043.43 | -$43.19 | -$5.05 | -$2.43 | -$2.56 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $1.1M | $2M | $390.4K | $995.5K | |
| Total Assets | -- | $2.3M | $32.9M | $19.4M | $1M | |
| Current Liabilities | -- | $14.1M | $11.7M | $11.5M | $12.8M | |
| Total Liabilities | -- | $14.1M | $13.1M | $12.4M | $12.8M | |
| Total Equity | -- | -$11.8M | $19.7M | $7M | -$11.7M | |
| Total Debt | -- | $4M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$9.7M | -$9.1M | -$5.9M | -$644.4K | -$1.4M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $2.1M | $7.7M | $6.3M | $647.8K | $1.9M | |
| Free Cash Flow | -$9.7M | -$9.1M | -$5.9M | -$644.4K | -$1.4M | |
ZVSA
Sector
Market Cap
$2.1M
$28.1M
Price % of 52-Week High
13.6%
51.87%
Dividend Yield
0%
0%
Shareholder Yield
-531.92%
-1.59%
1-Year Price Total Return
-77.53%
-17.31%
Beta (5-Year)
--
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.16
200-day SMA
Sell
Level
$0.35
Bollinger Bands (100)
Buy
Level
0.13 - 0.17
Chaikin Money Flow
Sell
Level
-286.2M
20-day SMA
Buy
Level
$0.14
Relative Strength Index (RSI14)
Buy
Level
89.26
ADX Line
Buy
Level
21.58
Williams %R
Sell
Level
-1.2739
50-day SMA
Buy
Level
$0.14
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Neutral
Level
487.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-9.5409)
Sell
CA Score
(Annual)
Level (-2.5844)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (11.3086)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.
Stock Forecast FAQ
In the current month, ZVSA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ZVSA average analyst price target in the past 3 months is $70.00.
-
Where Will ZyVersa Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that ZyVersa Therapeutics, Inc. share price will rise to $70.00 per share over the next 12 months.
-
What Do Analysts Say About ZyVersa Therapeutics, Inc.?
Analysts are divided on their view about ZyVersa Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ZyVersa Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is ZyVersa Therapeutics, Inc.'s Price Target?
The price target for ZyVersa Therapeutics, Inc. over the next 1-year time period is forecast to be $70.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ZVSA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ZyVersa Therapeutics, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of ZVSA?
You can purchase shares of ZyVersa Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ZyVersa Therapeutics, Inc. shares.
-
What Is The ZyVersa Therapeutics, Inc. Share Price Today?
ZyVersa Therapeutics, Inc. was last trading at $0.27 per share. This represents the most recent stock quote for ZyVersa Therapeutics, Inc.. Yesterday, ZyVersa Therapeutics, Inc. closed at $0.27 per share.
-
How To Buy ZyVersa Therapeutics, Inc. Stock Online?
In order to purchase ZyVersa Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ZVSA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ZVSA
Sector
P/E ratio
--
24.20x
PEG ratio
--
-0.01x
P/B ratio
0.19x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
ZVSA
Sector
Revenue growth
--
4.51%
Earnings growth
-5.31%
10.7%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$2.73
-$0.19
Profitability
ZVSA
Sector
Profitability FY 2024
-$6.9K
$3.5M
Return on invested capital
-711.85%
-32.3%
Return on assets
-157.27%
-28.57%
Return on equity
-711.85%
-38.09%
Earnings Date
Last Earnings Date
Nov
19
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Feb
18
Balance Sheet
ZVSA
Sector
Total cash
$528K
$26M
Short term investments
--
$25.7M
Total assets
$20.6M
$76.4M
Long term debt
--
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
